Table 5.
Clinicopathological characteristics according to molecular biomarkers in nGGO
| EGFR | ALK | P value* | |
|---|---|---|---|
| N |
119 |
6 |
|
| Age |
63.50 ± 9.11 |
60.00 ± 12.05 |
0.571 |
| Sex |
M:F = 43:76 |
M:F = 2:4 |
0.889 |
| PYR |
5.805 ± 14.426 |
0.750 ± 1.173 |
0.942 |
| Pathologic stage |
117† |
6 |
0.001 |
| 0 |
6 |
0 |
|
| IA |
87 |
1 |
|
| IB |
18 |
3 |
|
| IIA |
1 |
1 |
|
| IIB |
2 |
0 |
|
| IIIA |
3 |
1 |
|
| IIIB |
0 |
0 |
|
| Nodal involvement |
5 |
2 |
0.003 |
| Histologic invasiveness |
118** |
6 |
0.351 |
| AIS |
6 |
0 |
|
| MIA |
11 |
0 |
|
| IA |
101 |
6 |
|
| Maximal diameter |
22.387 ± 9.876 |
33.583 ± 13.736 |
0.032 |
| Solid diameter |
11.133 ± 11.229 |
23.217 ± 16.906 |
0.032 |
| TDR | 0.702 ± 0.295 | 0.533 ± 0.327 | 0.225 |
*P value: EGFR vs. ALK.
†Data for pathologic stage were unavailable for 2 patients.
**Data for histologic invasiveness were unavailable for 1 patient.